Biodegradable nanoparticles containing benzopsoralens : an attractive strategy for modifying vascular function in pathological skin disorders

作者: Anderson J Gomes , Laurelúcia O Lunardi , Flavio H Caetano , Antonio Eduardo H Machado , Ana Maria F Oliveira‐Campos

DOI: 10.1002/APP.33427

关键词:

摘要: Psoralens are often used to treat skin disorders such as psoriasis, vitiligo, and others. The toxicity fast degradation of these drugs can be diminished by encapsulation in drug-delivery systems (DDS). Nanoparticles (NPs) containing the benzopsoralen (BP) (3-ethoxy carbonyl-2H-benzofuro[3,2-e]-1-benzopiran-2-one) were prepared solvent-evaporation technique, parameters particle size, zeta potential, drug-encapsulation efficiency, external morphology evaluated. analysis revealed that NPs spherical with smooth surface diameter 815 ± 80 nm, they present low tendency toward aggregation, efficiency was 74%. intracellular distribution well their uptake tissues monitored using laser confocal microscopy transmission electron (TEM). use a BP association ultraviolet light (360 nm) TEM morphological characteristics cell damage cytosolic vesiculation, mitochondria condensation, swelling both granular endoplasmic reticulum nuclear membrane. primary target DDS vascular system endothelial cells an attractive strategy for modifying function various pathological states disorders, cancer, inflammation. results presented this work indicate poly(lactic-co-glycolic acid) NP should promising sustained release systemic local delivery associated irradiation (PUVA therapy). © 2011 Wiley Periodicals, Inc. J Appl Polym Sci,

参考文章(76)
Éric Dupont, Pierre Falardeau, Shaker A Mousa, Violetta Dimitriadou, Marie-Claude Pepin, Taiqi Wang, Moulay A Alaoui-Jamali, None, Antiangiogenic and antimetastatic properties of Neovastat (AE-941), an orally active extract derived from cartilage tissue. Clinical & Experimental Metastasis. ,vol. 19, pp. 145- 153 ,(2002) , 10.1023/A:1014546909573
Regina Heidenreich, Martin Röcken, Kamran Ghoreschi, Angiogenesis drives psoriasis pathogenesis International Journal of Experimental Pathology. ,vol. 90, pp. 232- 248 ,(2009) , 10.1111/J.1365-2613.2009.00669.X
Bryan P. Peters, Fred G. Weissman, Mark A. Gill, Pathophysiology and treatment of psoriasis American Journal of Health-system Pharmacy. ,vol. 57, pp. 645- 659 ,(2000) , 10.1093/AJHP/57.7.645
Paolo Rosina, Andrea Giovannini, Paolo Gisondi, Giampiero Girolomoni, Microcirculatory modifications of psoriatic lesions during topical therapy Skin Research and Technology. ,vol. 15, pp. 135- 138 ,(2009) , 10.1111/J.1600-0846.2008.00336.X
Taisuke Ito, Masahiro Aoshima, Natsuho Ito, Izumi Uchiyama, Keiko Sakamoto, Tetsuya Kawamura, Hiroaki Yagi, Hideo Hashizume, Masahiro Takigawa, Combination therapy with oral PUVA and corticosteroid for recalcitrant alopecia areata. Archives of Dermatological Research. ,vol. 301, pp. 373- 380 ,(2009) , 10.1007/S00403-009-0936-8
Giulia Meneghello, Daniel J. Parker, Benjamin J. Ainsworth, Semali P. Perera, Julian B. Chaudhuri, Marianne J. Ellis, Paul A. De Bank, Fabrication and characterization of poly(lactic-co-glycolic acid)/polyvinyl alcohol blended hollow fibre membranes for tissue engineering applications Journal of Membrane Science. ,vol. 344, pp. 55- 61 ,(2009) , 10.1016/J.MEMSCI.2009.07.034
A.J. Gomes, A.S. Faustino, C.N. Lunardi, L.O. Lunardi, A.E.H. Machado, Evaluation of nanoparticles loaded with benzopsoralen in rat peritoneal exudate cells International Journal of Pharmaceutics. ,vol. 332, pp. 153- 160 ,(2007) , 10.1016/J.IJPHARM.2006.09.035
Sahil A Parikh, Elazer R Edelman, Endothelial cell delivery for cardiovascular therapy. Advanced Drug Delivery Reviews. ,vol. 42, pp. 139- 161 ,(2000) , 10.1016/S0169-409X(00)00058-2
G BAIER, K ASADULLAH, U ZUGEL, The immunological synapse: kinases in T cell signalling as potential drug targets. Immunology Letters. ,vol. 105, pp. 3- 5 ,(2006) , 10.1016/J.IMLET.2005.12.003
Vivek Ranjan Sinha, A. Trehan, Biodegradable microspheres for parenteral delivery. Critical Reviews in Therapeutic Drug Carrier Systems. ,vol. 22, pp. 535- 602 ,(2005) , 10.1615/CRITREVTHERDRUGCARRIERSYST.V22.I6.20